Currently, there are 185.08M common shares owned by the public and among those 182.38M shares have been available to trade.
The company’s stock has a 5-day price change of 11.46% and -1.72% over the past three months. EXAS shares are trading -18.76% year to date (YTD), with the 12-month market performance down to -8.69% lower. It has a 12-month low price of $40.62 and touched a high of $79.62 over the same period. EXAS has an average intraday trading volume of 2.64 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 5.34%, -6.59%, and 3.46% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Exact Sciences Corp (NASDAQ: EXAS) shares accounts for 99.79% of the company’s 185.08M shares outstanding.
It has a market capitalization of $11.12B and a beta (3y monthly) value of 1.23. The earnings-per-share (ttm) stands at -$1.17. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.47% over the week and 5.13% over the month.
Earnings per share for the fiscal year are expected to decrease by -7.25%, and 77.86% over the next financial year.
Looking at the support for the EXAS, a number of firms have released research notes about the stock. Wells Fargo stated their Overweight rating for the stock in a research note on August 28, 2024, with the firm’s price target at $75. Scotiabank coverage for the Exact Sciences Corp (EXAS) stock in a research note released on June 27, 2024 offered a Sector Outperform rating with a price target of $70. Jefferies was of a view on June 03, 2024 that the stock is Buy, while The Benchmark Company gave the stock Buy rating on January 02, 2024, issuing a price target of $91. Guggenheim on their part issued Buy rating on December 14, 2023.
